Retatrutide
Also known as: LY3437943, Reta, Triple Agonist, Triple-G agonist
Retatrutide (LY3437943) is an investigational weekly GIP/GLP-1/glucagon triple agonist with large Phase 2 and Phase 3 weight-loss findings. It remains unapproved, and trial regimens or manufacturing timelines are not a prescribing label or guaranteed launch date.
Quick Facts
What is retatrutide?
Eli Lilly is developing retatrutide, LY3437943, as one molecule activating GIP, GLP-1 and glucagon receptors. The weekly subcutaneous program includes obesity, type 2 diabetes and fatty-liver-related conditions. Published 2026 Phase 3 data extend the earlier Phase 2 evidence, but it is still investigational.
How does it work?
GLP-1 and GIP are incretin targets that support glucose-dependent insulin secretion and influence appetite. Glucagon-receptor agonism is intended to increase energy expenditure and mobilize hepatic fat. The design motivates combined metabolic effects, but receptor count alone does not prove superiority to semaglutide or tirzepatide or isolate which receptor produced a particular outcome.
Is it FDA-approved?
Retatrutide has no FDA approval. Lilly has described a planned first-quarter 2027 filing, partly linked to manufacturing and quality verification; filing and review outcomes are not guaranteed. FDA states it is not a component of an approved drug and cannot be used in compounding under federal law. Authorized clinical research is distinct from prescription availability or online research-vial sales.
What does the research show?
| Study | Population and outcome |
|---|---|
| 2023 Phase 2 obesity | 338 randomized adults; at 48 weeks, weight changes were −17.1% in the combined 4 mg group, −22.8% at 8 mg and −24.2% at 12 mg versus −2.1% placebo. The 24-week endpoint was primary; 48-week weight was secondary. |
| Phase 2a MASLD substudy | The 2024 publication reported 98 participants over 24 weeks: relative liver-fat reductions of 81.4% at 8 mg and 82.4% at 12 mg versus a 0.3% increase on placebo. Liver fat tracked weight, abdominal-fat and metabolic changes; it is not equivalent to fibrosis or cardiovascular outcomes. |
| TRIUMPH-1 | 2,339 adults without diabetes over 80 weeks: treatment-regimen weight changes −17.6%, −23.7% and −25.0% at 4, 9 and 12 mg versus −3.9% placebo. |
| TRIUMPH-2 | 1,152 adults with obesity and type 2 diabetes over 80 weeks: treatment-regimen changes −11.9%, −16.8% and −18.8% at 4, 9 and 12 mg versus −5.1% placebo, with glycemic improvement. |
Phase 3 higher-dose weight results are often summarized as roughly 24–25% without diabetes or 17–19% with diabetes. Defined populations and estimands must remain attached. TRIUMPH-1 also reported favorable knee-osteoarthritis pain and sleep-apnea findings in defined subgroups.
Program scope, research exposure and safety
The four-trial TRIUMPH registrational program includes more than 5,800 participants. Phase 2 used 1, 4, 8 and 12 mg arms with different starting amounts; Phase 3 targeted 4, 9 and 12 mg. These weekly subcutaneous research regimens do not establish a universal 2 mg start, home reconstitution recipe or approved dose.
Phase 2 GI effects were dose related, mostly mild/moderate and less frequent with 2 mg rather than 4 mg starts. Heart-rate increases peaked at week 24 before declining. In TRIUMPH-2, diarrhea occurred in 27–34% and nausea in 14–28% versus 13% and 8% placebo. Hypotension and altered sensations were more frequent with retatrutide. Permanent discontinuation for adverse events or death was 4%, 12% and 8% across ascending active groups versus 5% placebo. Deaths occurred in all groups and investigators judged them unrelated; occurrence is not causation.
These findings do not establish the sterility, identity or safety of a different product sold under the same name.
Sources: [9]
References and further reading
This reference draws on Superpower’s Peptide Library and the research linked below. Peptide Dossier’s editorial team adapted and integrated the material on .
- ncbi.nlm.nih.govHow does it work?Cited in: How does it work?
- 10.1056/NEJMoa2604169How does it work?Cited in: How does it work?
- 10.1056/NEJMoa2301972What does the research show?Cited in: What does the research show?
- 10.1038/s41591-024-03018-2What does the research show?Cited in: What does the research show?
- 10.1016/S0140-6736(26)01861-1What does the research show?Cited in: What does the research show?
- sec.govIs it FDA-approved?Cited in: Is it FDA-approved?
- fda.govIs it FDA-approved?Cited in: Is it FDA-approved?
- pubmed.ncbi.nlm.nih.govWhat does the research show?Cited in: What does the research show?
- pubmed.ncbi.nlm.nih.govProgram scope, research exposure and safetyCited in: Program scope, research exposure and safety
- clinicaltrials.govIs it FDA-approved?Cited in: Is it FDA-approved?
- pubmed.ncbi.nlm.nih.govWhat does the research show?Cited in: What does the research show?
- pubmed.ncbi.nlm.nih.gov — additional reading
- pubmed.ncbi.nlm.nih.gov — additional reading
Frequently Asked Questions About Retatrutide
Published 2026 Phase 3 results are available, but retatrutide remains investigational and no guaranteed approval or commercial launch date is established here. FDA states that it cannot be used in compounding under federal law.
TRIUMPH-1 reported an 80-week treatment-regimen mean change of −25.0% at 12 mg versus −3.9% placebo in adults without diabetes. In TRIUMPH-2 with type 2 diabetes, the corresponding figures were −18.8% versus −5.1%. These are trial-group estimates, not an individual forecast.
The cited placebo-controlled trials do not establish head-to-head superiority to semaglutide or tirzepatide. Different populations, durations and analyses cannot be treated as one matched comparison.
A triple agonist activates three receptor systems. Retatrutide targets GIP, GLP-1 and glucagon receptors; this pharmacological identity does not by itself establish comparative clinical superiority.
It is not an FDA-approved marketed medicine. FDA explicitly states that retatrutide cannot be used in compounding under federal law. A research-only listing is not approval of a finished product; legitimate clinical research is a separate context.
No. It remains investigational. A planned first-quarter 2027 FDA filing is a development plan, not approval, and FDA states it cannot be used in compounding under federal law.
Tirzepatide targets GLP-1 and GIP; retatrutide adds glucagon-receptor agonism. The additional target is a pharmacological distinction, not proof of superior outcomes, and the products have different regulatory status.
At 48 weeks in Phase 2, 12 mg produced −24.2% versus −2.1% placebo. At 80 weeks in TRIUMPH-1, the 12 mg treatment-regimen estimate was −25.0% versus −3.9%. These are group estimates, not personal forecasts.
Lilly’s Phase 3 registrational program includes four trials and more than 5,800 participants, assessing weight management including cardiovascular-disease populations, sleep apnea and knee osteoarthritis. The design was published in 2026; a completed data package and planned filing still require regulatory review.
No approved retatrutide medicine is established here. FDA has warned about illegal unapproved sales, including products falsely presented as research-only. Authorized trial enrollment is a separate legitimate research access pathway.
Gastrointestinal effects were common, dose related and mostly mild/moderate in Phase 2; lower 2 mg starting groups had fewer than 4 mg starters. Later studies report additional population-specific events, and long-term safety is not settled by a short trial.
In the 98-person, 24-week MASLD study, relative hepatic-lipid reductions were 81.4% at 8 mg and 82.4% at 12 mg versus a 0.3% placebo increase. Those are liver-fat measurements, not proof of every downstream liver outcome.
Lilly has described a first-quarter 2027 filing plan. Commercial timing depends on filing, review, manufacturing and regulatory decisions; no launch date is guaranteed.
Related Peptides
Continue exploring Retatrutide
- Growth Hormone Peptides: Complete Guide to GH SecretagoguesGuide
- How to Get Retatrutide: Trial Search & Access ChecksGuide
- How to Reconstitute Retatrutide: Step-by-Step + Calculator (2026)Guide
- Ipamorelin vs Sermorelin: Growth Hormone Secretagogues Comparison 2026Comparison
- Ipamorelin vs Tesamorelin: GH Secretagogues ComparedComparison
- MK-677 (Ibutamoren): Complete Guide to the Oral Growth Hormone SecretagogueGuide
- Muscle Growth Peptides: GH Secretagogues & Anabolic Peptides [2026]Topic
- Peptides for Muscle Growth: Complete Guide to Growth Hormone SecretagoguesGuide
Our library review is ongoing. Read how we evaluate evidence or report a correction.
Disclaimer: This article is for informational and educational purposes only. It is not intended as medical advice. The information presented is based on published research and should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting any peptide protocol. Some peptides discussed may not be approved for human use by the FDA or equivalent regulatory bodies.